Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6115 | GSK 9027 |
| Glucocorticoid receptor agonist (pIC50 = 8). Inhibits production of the proinflammatory mediator IL-6 in vivo. | |
| BCC6116 | SB 772077B dihydrochloride |
| Potent Rho-kinase (ROCK) inhibitor (IC50 value of approximately 5.6 nM at recombinant human ROCK1 and 2). Decreases pulmonary and systemic arterial blood pressures and increases cardiac output. Exhibits vasodilator activity that is more potent than Y-27632 or Fasudil. | |
| BCC6119 | NPS 2390 |
| Group I mGlu antagonist; displays noncompetitive antagonist activity at both mGlu1 and mGlu5 receptors. Thought to act on a site separate from the glutamate binding pocket. | |
| BCC6120 | Conantokin G |
| GluN2B (formally NR2B) selective, competitive antagonist of the NMDA receptor. Blocks NMDA-evoked current in mouse cortical neurons (IC50 = 480 nM); also inhibits NMDA-evoked responses in oocytes expressing GluN2B (formally NR2B), but not GluN2A (formally NR2A), subunits (IC50 ~300 nM). Exhibits neuroprotective properties in vivo and in vitro. | |
| BCC6121 | TMN 355 |
| Potent cyclophilin A inhibitor (IC50 = 1.52 nM). Approximately 27 times more potent than cyclosporin A. | |
| BCC6122 | TCN 201 |
| NMDA receptor antagonist selective for GluN1/GluN2A (formally NR1/NR2A) over GluN1/GluN2B (formally NR1/NR2B) containing receptors (pIC50 values are 6.8 and <4.3, respectively, in human recombinant GluN1/GluN2A (formally NR1/NR2A) and GluN1/GluN2B (formally NR1/NR2B) FLIPR/Ca2+ assays). | |
| BCC6123 | TCN 213 |
| NMDA receptor antagonist, selective for GluN1/GluN2A (formally NR1/NR2A) (pIC50 = 5.4) over GluN1/GluN2B (formally NR1/NR2B) containing receptors. | |
| BCC6127 | MS 245 oxalate |
| High affinity 5-HT6 antagonist (Ki = 2.1 nM). Potentiates the hypolocomotor actions of (-)-nicotine in mice. | |
